Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
Status:
Terminated
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
This study is designed as a masked, two center, randomized, placebo-controlled pilot study to
evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects
with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth
University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential
subjects will be identified in each site's CF clinic.